BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Autor
Wepsięć Katarzyna (GSK Services Sp. z o.o., Warszawa, Poland), Mrożek-Gąsiorowska Magdalena A. (Pracownia HTA, Kraków, Poland), Gąsiorowski Marcin (Pracownia HTA, Kraków, Poland), Dankiewicz Oskar (Pracownia HTA, Kraków, Poland), Nowakowski Andrzej (Central Teaching Hospital, Warszawa, Poland)
Tytuł
Cost-Effectiveness Analysis of Human Papillomavirus (HPV) Vaccination Using Cervarix® as an Extension to the Cervical Cancer Prevention Programme in Poland
Źródło
Journal of Health Policy and Outcomes Research, 2013, nr 2, s. 32-41, rys., tab., bibliogr. 43 poz.
Słowa kluczowe
Profilaktyka zdrowotna, Ochrona zdrowia, Choroby
Preventive health care, Health care protection, Illness
Uwagi
summ.
Abstrakt
Background: The aim of the study was to estimate the cost-effectiveness of addition of human papillomavirus (HPV) vaccination to the Polish cervical cancer prevention programme. Methods: A cost-utility analysis was conducted. A lifetime Markov model, adapted to Polish settings, was used to compare the costs and health outcomes of the two strategies, i.e. the existing cervical cancer prevention programme with or without universal HPV vaccination in girls at the age of 14. Results: Assuming that the whole cohort was vaccinated (100% vaccination coverage), the estimated lifetime risk of developing cervical cancer would be reduced from 0.95% to 0.23%; therefore, 1311 cases of cervical cancer and 681 deaths due to cervical cancer would be prevented in a cohort of 182,000 girls aged 14 years.If the assumed vaccination coverage was 24%, the cost of gaining an additional quality-adjusted life year (QALY) due to HPV vaccination as an extension of the cervical cancer prevention programme would be PLN 52,737.91/QALY and PLN 76,288.47/QALY from the public payer's perspective and the common perspective of the public payer and the patient, respectively.This cost effectiveness is maintained for different parameter assumptions in the sensitivity analysis. Even with high assumed discount rates for costs and health outcomes (5% for both), the ICUR value was still lower than the cost-effectiveness threshold (PLN 105,801 per QALY). Conclusion: Addition of HPV vaccination to the cervical cancer prevention programme in Poland is a highly cost-effective intervention.(original abstract)
Pełny tekst
Pokaż
Bibliografia
Pokaż
  1. Urbański K., Kornafel J., Bidziński M. et al. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych u dorosłych; Krzakowski M., Via Medica, Gdańsk 2009; 234-242
  2. Raporty na podstawie danych Centrum Onkologii. Available from: http://epid.coi.waw.pl/krn/; [Accessed: 11 April 2013]
  3. Cancer Research UK. Cervical screening - results. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ cervix/screening/cervicalscreeningresults/cervical-screening-programme-results; [Accessed: 10 October 2013]
  4. de Villiers EM., Fauquet C., Broker TR., Bernard HU., zur Hausen H. Classification of papillomaviruses. Virology 2004 Jun 20; 324(1): 17-27
  5. Hirnle L. Zakażenia wirusami HPV - problem medyczny i społeczny. Gin Prakt 2009; 4: 8-12
  6. Macioch T., Niewada M., Wierzba W., Bidziński M., Radowicki S. Zapobieganie chorobom zależnym od zakażenia HPV - aspekty kliniczne i ekonomiczne stosowania szczepień profilaktycznych. Curr Gynecol Oncol 2010; 8(2): 69-81
  7. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries - an update. Stockholm: ECDC; 2012. Available from: http://ecdc.europa.eu/en/publications/publications/20120905_gui_hpv_vaccine_update.pdf; [Accessed: 11 April 2013]
  8. Komunikat Głównego Inspektora Sanitarnego z dnia 29 października 2012 r. w sprawie Programu Szczepień Ochronnych na rok 2013. Dziennik Urzędowy Ministra Zdrowia; Warszawa, dnia 30 października 2012 r.; poz. 78. Available from: http://dziennikmz.mz.gov.pl/DUM_MZ/2012/78/akt.pdf; [Accessed: 29 March 2013]
  9. Suárez E., Smith JS., Bosch FX. et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine. 2008 Sep 15; 26 Suppl 5: F29-45
  10. Demarteau N., Detournay B., Tehard B., El Hasnaoui A., Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health. 2011 Apr; 56(2): 153-162
  11. Demarteau N., Tang CH., Chen HC., Chen CJ., Van Kriekinge G. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Value Health. 2012 Jul-Aug; 15(5): 622-631
  12. Agencja Oceny Technologii Medycznych. Informacja w sprawie obowiązującej wysokości progu kosztu uzyskania dodatkowego roku życia skorygowanego o jakość. Available from: http://www.aotm.gov.pl/index.php?id=677; [Accessed: 11 April 2013]
  13. Charakterystyka Produktu Leczniczego Cervarix®. Available from: http://www.ema.europa.eu/docs/pl_PL/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf; [Accessed: 25 March 2013]
  14. Kotarski J., Basta A., Dębski R. et al. Uzupełnione stanowisko Polskiego Towarzystwa Ginekologicznego dotyczące szczepień przeciwko zakażeniom wirusami brodawczaka ludzkiego (HPV) (stan wiedzy na dzień 19 września 2009 r.). Ginekol Pol 2009; 80: 870-876
  15. Chybicka A., Jackowska T., Dobrzańska A. et al. Zalecenia grupy ekspertów dotyczące pierwotnej profilaktyki raka szyjki macicy u dziewcząt i młodych kobiet. Pediatr Pol 2010; 85(4): 360-370
  16. Majewski S., Sikorski M. Rekomendacje Polskiego Towarzystwa Profilaktyki Zakażeń HPV (PTPZ-HPV) dotyczące stosowania profilaktycznych szczepionek przeciw HPV. Przew Lek 2008; 1: 222-227
  17. Majewski S., Sikorski M. Przełom w pierwotnej profilaktyce raka szyjki macicy i innych zmian związanych z zakażeniem HPV. Przew Lek 2007; 2: 108-113
  18. Badanie Zbigniewa Izdebskiego i Polpharmy Seksualność Polaków 2011. Available from: http://www.termedia.pl/badanie-zbigniewa-izdebskiego-i-polpharmy-seksualnosc-polakow-2011-,5152.html [Accessed: 18 July 2013]
  19. Lehtinen M., Paavonen J., Wheeler CM. et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012 Jan; 13(1): 89-99
  20. Paavonen J., Jenkins D., Bosch FX. et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 Jun 30; 369(9580): 2161-2170
  21. Paavonen J., Naud P., Salmeron J. et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet 2009 Jul 25; 374(9686): 301-314
  22. Szarewski A., Poppe WA., Skinner SR. et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012 Jul 1; 131(1): 106-116
  23. Wheeler CM., Castellsague X., Garland SM. et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012 Jan; 13(1): 100-110
  24. WHO/ICO Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer. Available from: http://apps.who.int/hpvcentre/statistics/dynamic/ico/DataQuerySelect.cfm; [Accessed: 27 March 2013]
  25. Aubin F., Prétet JL., Jacquard AC. et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis. 2008 Sep 1; 47(5): 610-615
  26. Fahey MT., Irwig L., Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995 APr 1; 141(7): 680-689
  27. Garland SM., Hernandez-Avila M., Wheeler CM. et al.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 May 10; 356(19): 1928-1943
  28. Harper DM., Franco EL., Wheeler CM. et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006 April 15; 367(9518): 1247-1255
  29. Insinga R., Glass A., Rush B. Health state transitions following an abnormal pap smear: implications for health utility assessment in cost-effectiveness analyses (abstrakt W-02 - 22nd International Papillomavirus Conference & Clinical Workshop 2005, Canada 2005)
  30. Munoz N., Kjaer SK., Sigurdsson K. et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010 Mar 3; 102(5): 325-339
  31. Myers ER., Green S., Lipkus I. Patient preferences for health states related to HPV infection: visual analog scale versus time trade-off elicitation (abstrakt nr 542 - Twenty-First International Papillomavirus Conference, México 2004)
  32. Smeets F., De Deken L., Baeten RFG. Cervixkankerscreening. Aanbeveling voor goede medische praktijkvoering. Huisarts Nu. 2002; 31(6): 275-295
  33. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10; 356(19): 1915-1927
  34. Tjalma W., Paavonen J., Naud P. et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naive population. Int J Gynecol Cancer 2009; 19(Suppl.2): 1008
  35. Woodhall SC., Jit M., Soldan K. et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011 Oct; 87(6): 458-463
  36. Medycyna Praktyczna. Indeks leków (dane z dnia 21 marca 2013 r.). Available from: http://indeks.mp.pl/; [Accessed: 21 March 2013]
  37. Armstrong EP.: Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010 Apr; 16(3): 217-230
  38. Barnabas RV., Kulasingam SL. Economic evaluations of human papillomavirus vaccines. Expert Rev Pharmacoecon Outcomes Res. 2007 Jun; 7(3): 251-267
  39. Brisson M., Van de Velde N., De Wals P., Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007 Jul 20; 25(29): 5399-5408
  40. Colantonio L., Gómez JA., Demarteau N., Standaert B., Pichón-Rivière A., Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine. 2009 Sep 4; 27(40): 5519-5529
  41. Koleva D., De Compadri P., Padula A., Garattini L. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Intern Emerg Med. 2011 Apr; 6(2): 163-174
  42. Marra F., Cloutier K., Oteng B., Marra C., Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine. A systematic review. Pharmacoeconomics. 2009; 27(2): 127-147
  43. Nowakowski A., Jackowska T., Oszukowski PJ., Radowicki S., Wysocki J., Zatoński W. Profilaktyka raka szyjki macicy - problem interdyscyplinarny. Czy i jak możemy poprawić sytuację w Polsce?. Pediatr Pol. (2013). Available from: http://dx.doi.org/10.1016/j.pepo.2013.05.005; [Accessed: 10 October 2013]
Cytowane przez
Pokaż
ISSN
2299-1247
Język
eng
URI / DOI
http://dx.doi.org/10.7365/JHPOR.2013.4.4
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu